Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can newer cataract lenses keep vision clear for years?

NCT ID NCT05796453

Disease control Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study follows adults who had cataract surgery with Clareon Vivity or PanOptix intraocular lenses, which are designed to restore vision at multiple distances. Researchers will track visual acuity and watch for complications like lens dislocation or retinal detachment over several years. The goal is to see whether these lenses remain safe and perform well long after implantation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clareon Vivity, Vivity Toric, PanOptix, and PanOptix Toric intraocular lenses (IOLs)
What this could lead to
If successful, this study could confirm that these lenses remain safe and effective for years, supporting their continued use in cataract surgery to restore vision at multiple distances.
What could go wrong
This is an observational follow-up, not a randomized trial, so it cannot prove these lenses are better than others. Possible risks include lens dislocation, retinal detachment, or the need for a second surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

470 people

The number who actually took part.

Started

Sep 2023

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Subject or legally authorized representative must be able to understand and sign an approved Informed Consent Form. * Subject must have had bilateral implantation of Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOLs between 3-6 months prior to enrollment. * Subject must have a documented medical history and required pre-operative baseline information available for retrospective data collection. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Subject is currently participating in another investigational drug or device study. * Subject has had corneal refractive surgery after Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOL implantation. * Subject is pregnant at the time of enrollment. * Other protocol-defined exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aphakia astigmatism congenital primary aphakia presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aphakia Astigmatism Presbyopia

Contacts and locations

Locations

  • Centro Oftalmologico Metropolitano

    San Juan, 00921, Puerto Rico

  • Chu Eye Institute

    Fort Worth, Texas, 76107, United States

  • Eye Surgeons of CNY

    Liverpool, New York, 13088, United States

  • Levenson Eye Associates

    Jacksonville, Florida, 32204, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • Tulsa Ophthalmology

    Tulsa, Oklahoma, 74104, United States

  • Wolstan & Goldberg Eye Associates

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.